Assignee
AZURA OPHTHALMICS LTD
IL·20 granted patents·22 pending applications·89 citations·filing 2016–2025
Top patents by PatentIndex Score
42 records- 0198US10688122B2Thiol and disulfide-containing agents for increasing meibomian gland lipid secretionAZURA OPHTHALMICS LTD·Filed 2016·Granted Jun 23, 2020·18 cites·11 claims
- 0297US12048707B2Compositions and methods for the treatment of meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2023·Granted Jul 30, 2024·3 cites·1 claims
- 0397US11633410B2Compositions and methods for the treatment of meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2021·Granted Apr 25, 2023·6 cites·20 claims
- 0497US11013749B2Compositions and methods for the treatment of meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2020·Granted May 25, 2021·7 cites·20 claims
- 0597US10772899B2Compositions and methods for the treatment of meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2019·Granted Sep 15, 2020·8 cites·30 claims
- 0697US10588915B2Compositions and methods for the treatment of meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2018·Granted Mar 17, 2020·19 cites·14 claims
- 0795US12011457B2Selenium disulfide compositions for use in treating meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2021·Granted Jun 18, 2024·3 cites·27 claims
- 0895US11324775B2Compositions and methods for the treatment of contact lens discomfortAZURA OPHTHALMICS LTD·Filed 2021·Granted May 10, 2022·8 cites·20 claims
- 0994US11040062B2Selenium disulfide compositions for use in treating meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2017·Granted Jun 22, 2021·8 cites·22 claims
- 1094US10875845B2Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2020·Granted Dec 29, 2020·4 cites·20 claims
- 1193US11517586B2Instructions for composition and sensitivityAZURA OPHTHALMICS LTD·Filed 2021·Granted Dec 6, 2022·2 cites·19 claims
- 1291US12447162B2Compositions and methods for the treatment of meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2024·Granted Oct 21, 2025·0 cites·27 claims
- 1391US12427158B2Compositions and methods for the treatment of meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2024·Granted Sep 30, 2025·0 cites·30 claims
- 1488US12458661B2Selenium disulfide compositions for use in treating meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2024·Granted Nov 4, 2025·0 cites·29 claims
- 1588US12083147B2Compositions and methods for the treatment of contact lens discomfortAZURA OPHTHALMICS LTD·Filed 2022·Granted Sep 10, 2024·1 cites·20 claims
- 1687US2026021135A1Selenium disulfide compositions for use in treating meibomian gland dysfunctionAZURA OPHTHALMICS LTD·Filed 2025·Application pending·0 cites
- 1786US11459351B1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Granted Oct 4, 2022·1 cites·16 claims
- 1884US11634411B2Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2020·Granted Apr 25, 2023·1 cites·1 claims
- 1979US2025099500A1Compositions and methods for the treatment of contact lens discomfortAZURA OPHTHALMICS LTD·Filed 2024·Application pending·0 cites
- 2078US2025042931A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2024·Application pending·0 cites
- 2174US2023357207A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2023·Application pending·0 cites
- 2274US2023346832A1Instructions for composition and sensitivityAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 2372US2022409657A1Instructions for composition and sensitivityAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 2472US2023348517A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2023·Application pending·0 cites
- 2571US2022332749A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 2671US2022226367A1Thiol and disulfide-containing agents for increasing meibomian gland lipid secretionAZURA OPHTHALMICS LTD·Filed 2021·Application pending·0 cites
- 2769US11643429B2Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Granted May 9, 2023·0 cites·20 claims
- 2865US2023013824A1Compositions for the treatment of hyperkeratosis disordersAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 2964US2020179440A1Thiol and disulfide-containing agents for increasing meibomian gland lipid secretionAZURA OPHTHALMICS LTD·Filed 2020·Application pending·0 cites
- 3064US2025262331A1Composition and methods for improving signs and symptoms of ocular disordersAZURA OPHTHALMICS LTD·Filed 2025·Application pending·0 cites
- 3160US2022305052A1Metered dose for disorders in or around the eyeAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 3259US2022323487A1Metered dose for demodex and disorders related theretoAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 3359US2026053711A1Semi-solid pharmaceutical composition micro-dispenserAZURA OPHTHALMICS LTD·Filed 2025·Application pending·0 cites
- 3457US12527817B2Manufacturing of selenium disulfide compositionsAZURA OPHTHALMICS LTD·Filed 2022·Granted Jan 20, 2026·0 cites·15 claims
- 3557US2024285679A1Compositions and methods for vision improvementAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 3656US2024158375A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Application pending·0 cites
- 3756US2026055110A1Compounds and methods for the treatment of dermal and ocular disordersAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 3854US2023399317A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Application pending·0 cites
- 3950US2021161707A1Dispenser for precise extraction of a semi-solid productAZURA OPHTHALMICS LTD·Filed 2021·Application pending·0 cites
- 4050US2023000675A1Device for administering drug to eyelidAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 4146US11484516B2Agents for increasing meibomian gland lipid secretionAZURA OPHTHALMICS LTD·Filed 2018·Granted Nov 1, 2022·0 cites·16 claims
- 4246US2020179305A1Compositions for the Treatment of Hyperkeratosis DisordersAZURA OPHTHALMICS LTD·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →